In 2017, CBDepot introduced a pharmaceutical good manufacturing practice (GMP) natural cannabinoid (CBD) isolate to the active pharmaceutical ingredients (API) segment during CPhI Frankfurt.
CBDepot’s work has been constantly driven by innovations. The company has been bringing newly isolated cannabinoids and preparations for food and food supplement sectors to market, which tackle the novel food regulation on hemp derivatives in the EU.
In November 2017, CBDepot and its distribution partner Farmakem won a tender for deliveries of GMP CBD to a public paediatric hospital in Ljubljana, Slovenia, for a co-treatment of child epilepsy. Farmakem played a vital role by regulatory development of the product and in the process of public tender.
This is a major breakthrough in cannabinoid-based therapies in the EU and could not happen without the dedication of Farmakem and Prof Dr Neubauer.
Neubauer has a long record of clinical experience in treating his paediatric patients with CBD and reports the best outcomes when CBD of natural origin is being administered to his patients.
In 2019, this active substance has been confirmed as the substance of choice at the paediatric hospital in Ljubljana and additionally also in the tender at the Institute of Oncology in Ljubljana.